Vismodegib Dosage

Medically reviewed on April 10, 2017.

Usual Adult Dose for Basal Cell Carcinoma

Usual adult dose: 150 mg orally once a day

Duration of therapy: Until disease progression or until unacceptable toxicity.

Use: Treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

No dosage adjustment is recommended based on gender, weight, or age.

Precautions

US BOXED WARNING:
-Vismodegib can result in embryo-fetal death or severe birth defects.
-Vismodegib is embryotoxic and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.
-Verify pregnancy status prior to the initiation of vismodegib. Advise male and female patients of these risks. Advise female patients of the need for contraception and advise male patients of the potential risk of vismodegib exposure through semen.

Safety and efficacy have not been established in patients younger than 18 years.

Dialysis

Data not available

Other Comments

Administration advice:
-May be taken with or without food.
-Swallow capsules whole; do not open or crush capsules.
-If a dose of is missed, do not make up that dose; resume dosing with the next scheduled dose.

Monitoring:
-Pregnancy

Patient advice:
-Advise patients that exposure during pregnancy can cause embryo-fetal death or severe birth defects.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer